Management of hematological toxicities after BCMA-directed CAR-T cell therapy - PubMed
7 hours ago
- #hematotoxicity
- #CAR-T therapy
- #multiple myeloma
- The CAR-HEMATOTOX (CAR-HT) score predicts hematotoxicity risk in multiple myeloma patients receiving BCMA-directed CAR-T therapy.
- High CAR-HT scores (≥2) are linked to higher rates of severe anemia, thrombocytopenia, and increased need for transfusions.
- Stem cell boosts showed rapid trilineage recovery, but intensive interventions raised infection risks without affecting survival outcomes.
- The CAR-HT score serves as a practical clinical tool for guiding supportive care, including transfusion management.